Castle Biosciences (CSTL) Expected to Announce Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $83.89 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Castle Biosciences Price Performance

CSTL opened at $25.36 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The stock has a market capitalization of $710.33 million, a P/E ratio of 126.81 and a beta of 0.91. The company’s 50 day simple moving average is $27.46 and its 200-day simple moving average is $29.26. Castle Biosciences has a one year low of $16.97 and a one year high of $35.84.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,972 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $31.35, for a total transaction of $61,822.20. Following the completion of the transaction, the insider now directly owns 85,748 shares of the company’s stock, valued at approximately $2,688,199.80. This represents a 2.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel Bradbury sold 7,867 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. Insiders have sold 30,771 shares of company stock worth $886,112 over the last ninety days. Insiders own 7.20% of the company’s stock.

Analyst Upgrades and Downgrades

CSTL has been the topic of a number of research reports. Lake Street Capital lifted their price target on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group increased their target price on Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Stephens restated an “overweight” rating and issued a $41.00 price target on shares of Castle Biosciences in a report on Thursday, January 2nd. KeyCorp increased their price objective on Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Finally, Robert W. Baird raised their target price on shares of Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Castle Biosciences presently has a consensus rating of “Buy” and a consensus target price of $40.29.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.